Prometic presents PBI-4050 and PBI-4547 in Vivo Data at American Association for the Study of Liver Diseases (AASLD) Meeting

LAVAL, QC, Oct. 20, 2017 /CNW Telbec/ - Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (Prometic) today announces in vivo data from compounds PBI-4050 and PBI-4547 for the prevention and treatment of liver diseases, and associated metabolic syndrome are being presented in three poster sessions at AASLD (The Liver Meeting®) in Washington, D.C. from Oct. 20-24, 2017. 

"We are excited by the implications of our data and the promise of our candidates PBI-4050 and PBI-4547 for the treatment and prevention of liver diseases," said Pierre Laurin, president and chief executive officer, Prometic. "These results in varying mouse models of liver disease demonstrate Prometic's ability to target multiple indications, including hepatic fibrosis, metabolic syndrome, and non-alcoholic fatty liver disease."

PBI-4050, a novel first-in-class oral compound, also is currently in clinical phase II study for diabetic patients with metabolic syndrome.

About PBI-4050 data:

The first poster, entitled: PBI-4050 Inhibits Hepatic Stellate Cell Proliferation and Activation Via AMPK, and Improves Hepatic Fibrosis in CCL4-Induced Liver Injury Model, examined PBI-4050's ability to decrease hepatic stellate cell (HSC) activation via AMPK and prevent fibrosis in mice. Results of the study showed PBI-4050 is a potential novel therapy for hepatic fibrosis.

Presentation details: Publication # 392, October 20, 2017 from 8:00 AM - 5:30 PM, Session: Basic Fibrosis Research and Stellate Cell Biology, Washington Convention Center, Hall D

The second poster, entitled: PBI-4050 Reduces Liver Damage and Fibrosis in a High-Fat Diet Mouse Model of Obesity and Metabolic Syndrome, demonstrated improvements in glucose metabolism, serum triglycerides, hepatic steatosis and ballooning in the liver in a mouse model of non-alcoholic fatty liver disease (NAFLD) after dosing with PBI-4050. These data suggest an important clinical application of PBI-4050 in the prevention of liver diseases. 

Presentation details:  Publication # 2016, October 23, 2017 from 8:00 AM to 5:30 PM

Session: Steatohepatitis: Experimental, Washington Convention Center, Hall D

About PBI-4547 data:

The third poster, entitled: PBI-4547 Reverses Liver Steatosis and Fibrosis, and Improves Metabolic Syndrome in ob/ob Mice, presented results from ob/ob mice orally dosed with PBI-4547, demonstrating reduction in blood levels of glucose, cholesterol, and triglyceride, in fibrosis/cell infiltration, in liver steatosis and hepatocellular ballooning. These data suggest PBI-4547 is a potential novel therapy for NAFLD, obesity, and metabolic syndrome.

Presentation details: Publication # 2017, October 23, 2017 from 8:00 AM to 5:30 PM,

Session: Steatohepatitis: Experimental, Location: Washington Convention Center, Hall D

About AASLD

The AASLD conference is an annual conference that highlights the latest liver diseases research and discusses treatment outcomes with physicians, researchers and healthcare practitioners involved in the science and practice of hepatology.

About Prometic Life Sciences Inc.
Prometic Life Sciences Inc. (www.prometic.com) is a long-established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development.  Prometic is active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small molecule products are under development for orphan drug indications. Prometic also offers its state-of-the-art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe and Asia.

Forward Looking Statements        
This press release contains forward-looking statements about Prometic's objectives, strategies and businesses that involve risks and uncertainties. These statements are "forward-looking" because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic's ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic's Annual Information Form for the year ended December 31, 2016, under the heading "Risk and Uncertainties related to Prometic's business".  As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations.  All amounts are in Canadian dollars unless indicated otherwise.

SOURCE ProMetic Life Sciences Inc.